Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2019-03-11
2022-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Terbutaline Concentrations in Blood and Urine
NCT00914797
Beclomethasone in Healthy Athletes
NCT05352191
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.
NCT04757532
Dopaminergic Effects on Brown Adipose Tissue
NCT02428933
Role of K+ and Ca2+ in Development of Muscle Fatigue
NCT02712658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
First phase sequential Second phase crossover
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clenbuterol
Subjects ingest 80 micrograms of clenbuterol tablets
Clenbuterol Oral Product
Subjects ingest 4x20 microgram clenbuterol tablets
Placebo
Subjects ingest placebo tablets
Placebo
Subjects ingest placebo tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clenbuterol Oral Product
Subjects ingest 4x20 microgram clenbuterol tablets
Placebo
Subjects ingest placebo tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male
* 18-40 years of age
* No known contraindications for anabolic drugs (e.g. cancer)
Exclusion Criteria
* Steroid abuse
* Ongoing use of prescription medication
* heavy resistance training more than 2 times weekly
* Disease deemed by the MD to infer a risk to participate in the trial
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
August Krogh Building
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLEN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.